ArticleFrontiers in molecular biosciences2023
The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.
Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrLMolecular psychiatry · 2026Article
- A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026Article
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- Characterizing non-hallucinogenic psychedelics beyond the head twitch response: phenotypic fingerprinting of lisuride and LSD.Translational psychiatry · 2026Article
- Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026Review
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- Psychedelic 5-HTNature neuroscience · 2025Article
- Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.Fundamental & clinical pharmacology · 2025Review
- Across preclinical and clinical platforms, approved and investigational psychiatric drugs share pathways and associate with similar molecular functions.Frontiers in drug discovery · 2025Article
- Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited.ACS pharmacology & translational science · 2024Article
- Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Biological studies of clavine alkaloids targeting CNS receptors.Frontiers in psychiatry · 2023Article
Corrections and comments
- Update of
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
There is now evidence from multiple Phase II clinical trials that psychedelic drugs can exert long-lasting anxiolytic, anti-depressant, and anti-drug abuse (nicotine and ethanol) effects in patients. Despite these benefits, the hallucinogenic actions of these drugs at the serotonin 2A receptor (5-HT2AR) limit their clinical use in diverse settings. Activation of the 5-HT2AR can stimulate both G protein and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.